TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
(b) On February 16, 2019, Charles Mather, age 58, notified the Board of Directors (the “Board”) of Tonix Pharmaceuticals Holding Corp. (the “Company”) that he was resigning from the Board effective immediately. Mr. Mather was a member of the Audit Committee and Governance and Nominating Committee (the “NCG Committee”). Mr. Mather did not resign from the Board due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
(d) On February 14, 2019, the Board, on the recommendation of the NCG Committee, appointed James Treco, as director of the Company, effective immediately. Mr. Treco will serve on the Audit Committee of the Board.
Mr. Treco, age 63, is a Managing Partner at First Chicago Advisors, Inc., a boutique financial advisory firm where he advises executives and boards of directors of a wide range of companies, from global, large-cap companies to emerging companies He has served in that capacity since 2014 and previously from 2009 to 2012. From 2012 to 2013 Mr. Treco was an investment banker with Gleacher & Company, a company that previously operated an investment banking business, providing corporate and institutional clients with strategic and financial advisory services. Mr. Treco held various positions of increasing responsibility at Salomon Brothers/Citigroup from 1984 to 2008, where he used his extensive experience in the global capital markets to advise a wide range of clients. During his career he has worked with various biotechnology companies. For the past decade, he has been involved with start-up companies affiliated with Dartmouth Hitchcock Medical Center in Hanover, New Hampshire developing intellectual properties, a number of which have been sold and licensed to larger, publicly-traded pharmaceutical companies. Mr. Treco holds a B.A. from Yale University and an M.B.A. from the Stanford University Graduate School of Business. Mr. Treco’s extensive healthcare and investment banking experience were instrumental in his selection as a member of the Board.
The Board awarded Mr. Treco 10,000 stock options, which vest on the Company’s 2019 annual meeting of shareholders and are exercisable at $1.86 per share.
There are no arrangements or understandings to which Mr. Treco was appointed as a director, and there are no related party transactions between the Company and Mr. Treco reportable under Item 404(a) of Regulation S-K.
| Item 7.01 | Regulation FD Disclosure. |
A copy of the press release announcing Mr. Treco’s appointment to the Board is furnished as Exhibit 99.01.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibit No. | Description | |
| 99.01 | Press Release date February 19, 2019 issued by the Company |
Tonix Pharmaceuticals Holding Corp. Exhibit
EX-99.1 2 ex99-1.htm PRESS RELEASE Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.1 Tonix Pharmaceuticals Announces New Board Member,…
To view the full exhibit click here